A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Inclusion Criteria:

• Participant has stable moderate to severe plaque psoriasis for at least 6 months
• Participant has a score of PASI ≥ 12, involvement of ≥ 10% body surface area andstatic Physician Global Assessment ≥ 3 at screening and at baseline
• Participant is a candidate for phototherapy or systemic therapy
• Participant has previous failure, inadequate response, intolerance, orcontraindication to at least 1 conventional antipsoriatic systemic therapy
• Female participant should have a negative serum pregnancy test during screening and anegative urine pregnancy test at baseline
• Participant or legally acceptable representative is capable of giving signedInstitutional Review Board (IRB)/Independent Ethics Committee (IEC) informed consent
• Participant has no known history of latent or active tuberculosis
• Participant with a positive purified protein derivative (PPD) test and a history ofBacillus Calmette-Guérin (BCG) vaccination is allowed with a negativeQuantiferon/T-spot test
• Participant with a positive PPD test or participant with a positive or indeterminateQuantiferon/T-spot test is allowed if he/she has all the following:
• No symptoms per tuberculosis worksheet provided by the sponsor, Amgen Inc.
• Documented history of adequate prophylaxis initiation prior to receivinginvestigational product in accordance with local recommendations
• No known exposure to a case of active tuberculosis after most recent prophylaxis
• No evidence of active tuberculosis on chest radiograph within 3 months prior tothe first dose of investigational product

Exclusion Criteria:

• Participant has erythrodermic psoriasis, pustular psoriasis, guttate psoriasis,medication induced psoriasis, or other skin conditions at the time of screening (eg,eczema) that would interfere with evaluations of the effect of investigational productof psoriasis
• Participant has an active infection or history of infections
• Participant has uncontrolled, clinically significant systemic disease, such asuncontrolled diabetes mellitus, cardiovascular disease, renal disease, liver disease,or hypertension
• Participant has a mean QT internal or abnormal long QT syndrome corrected usingFridericia's formula (QTcF) of > 450 msec (for male participant) or > 470 msec (forfemale participant) at baseline that, in the opinion of the Investigator, is abnormalor clinically significant
• Participant has moderate to severe heart failure (New York Heart Associate classIII/IV)
• Participant has known hypersensitivity to the investigational product or to any of theexcipients
• Participant has laboratory abnormalities at screening
• Participant has had previous treatment with any agent specifically targetinginterleukin (IL)-12 or IL-23 within 1 year prior to enrollment
• Participant has received biologic treatment for psoriasis within the previous month or 5 drug half-lives (whichever is longer) prior to enrollment
• Participant has received any investigational agents within the previous month or 5half-lives (whichever is longer) prior to enrollment
• Participant has received non-biologic systemic psoriasis therapy within 4 weeks priorto enrollment
• Participant has received ultraviolet A phototherapy (with or without psoralen) orexcimer laser within 4 weeks prior to enrollment, or ultraviolet B phototherapy within 2 weeks prior to enrollment
• Participant has received topical psoriasis treatment within 2 weeks prior toenrollment
• Participant has received other investigational procedures within 4 weeks prior toenrollment and during the course of the study
• Female participant is pregnant or breastfeeding or planning to become pregnant whileparticipating in the study and for at least 5 months after the last dose ofinvestigational product
• Sexually active participants and their partners who are of childbearing potential andnot agreeing to use adequate protocol defined contraception methods whileparticipating in the study and for 5 months after the last dose of investigationalproduct